Clinical Trials · NCT03860987
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 12
- Start date
- Apr 2019
- Locations
- 1 site, United States
- Primary endpoint
- disease status